ArticleMolecular therapy. Oncology2024
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade.
Abstract read
In one paragraph
Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Advances in oncolytic virus delivery strategies and challenges in clinical translation.Materials today. Bio · 2026Review
- Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies.Therapeutic advances in medical oncology · 2026Review
- Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends.Current oncology (Toronto, Ont.) · 2025Review
- Cracking the code for more effective treatments for hepatocellular carcinomas: Promise and a path for immunovirotherapy.Molecular therapy. Oncology · 2025Article
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models.Frontiers in immunology · 2025Article
- Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer's defenses.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Mulu Z TesfayDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Yuguo ZhangDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Khandoker U FerdousDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Mika A TaylorDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Aleksandra CiosDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Randal S SheltonDepartment of Pharmacology, UAMS, Little Rock, AR, USA.
Camila C SimoesDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Chelsae R WattersDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Oumar BarroDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Natalie M ElliottDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Bahaa MustafaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Jean Christopher ChamcheuSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA, USA.
Alicia L GrahamDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Charity L WashamThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Duah AlkamThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Allen GiesThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Stephanie D ByrumThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Emmanouil GiorgakisCollege of Medicine, Surgery Transplant University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Steven R PostDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Thomas KellyDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Jun YingDepartment of Biostatistics, UAMS College of Public Health, Little Rock, AR, USA.
Omeed MoavenDivision of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health, New Orleans, LA, USA.
Chiswili Y ChabuDivision of Biological Sciences, University of Missouri, Columbia, MO, USA.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, USA.
Dan G DudaEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Lewis R RobertsSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, MN, USA.
Rang GovindarajanMedical Oncology Division, Internal Medicine Department, The University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mitesh J BoradDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Martin J CannonThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Alexei G BasnakianThe Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR, USA.
Bolni M NagaloDepartment of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Funding
Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett · 2017 to 2026
$27.6MSupplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4MOncolytic Virotherapy in Hepatocellular CancerDP2CA195764 · NCI · MAYO CLINIC ARIZONA · PI BORAD, MITESH · 2014 to 2016
$2.7MNovel Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic CancerDP2CA301099 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAGALO, BOLNI MARIUS · 2024 to 2024
$1.4MIntegrated molecular epidemiologic analysis of the one-carbon metabolism pathway and risk of HCCK01CA237875 · NCI · MAYO CLINIC JACKSONVILLE · PI ANTWI, SAMUEL O. · 2020 to 2024
$829kcGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular CarcinomaK01CA234324 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAGALO, BOLNI MARIUS · 2018 to 2022
$667kHarnessing the potential of pharmacological small molecules to amplify VSV-based oncolytic viral therapyR15CA290568 · NCI · SOUTHERN UNIV A&M COL BATON ROUGE · PI CHAMCHEU, JEAN CHRISTOPHER · 2024 to 2024
$409kBLRD VA I01 BX002425BLRD VA IK6 BX006184NCI NIH HHS DP2 CA195764NCI NIH HHS DP2 CA301099NCI NIH HHS K01 CA234324NCI NIH HHS K01 CA237875NCI NIH HHS R15 CA290568NIGMS NIH HHS P20 GM121293NIGMS NIH HHS R24 GM137786
Abstract
Members of the
Indexed as
hepatocellular carcinomaJurona virusoncolytic virusRhabdoviridaevesiculovirus
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.